At a glance
ClinicalIndex Comparison RecordN/ACompleted· 10 enrolled
Drug / intervention
active rTMS first, then sham rTMS +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
TMS Related Biomarker Assessments
In Brief
A clinical study evaluating active rTMS first, then sham rTMS and sham rTMS first, then active rTMS for Schizophrenia Schizoaffective and Schizophrenia. Completed, enrolled 10 participants across 1 site.
Detailed Summary
Patients with schizophrenia spectrum disorder (SSD) will be exposed to active and sham repetitive transcranial magnetic stimulation (rTMS) in separate sessions. SSD-related biomarkers will be assessed before and after the rTMS administration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia Schizoaffective, Schizophrenia
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2023202420252026
First PostedDec 2022
Enrollment StartJan 2023
Primary CompletionFeb 2025
TodayJul 2026
First PostedDec 21, 2022
Enrollment StartJan 7, 2023
Primary CompletionFeb 14, 2025
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 3.5 years ago
Interventions
active rTMS first, then sham rTMSdevice
Active rTMS is delivered on the first visit, then sham rTMS is delivered on the second visit.
sham rTMS first, then active rTMSdevice
Sham rTMS is delivered on the first visit, then active rTMS is delivered on the second visit.